載入...
Benefits versus risks of latest therapies in multiple sclerosis: a perspective review
Disease-modifying treatments for multiple sclerosis (MS) have now been available for almost 20 years. Interferon β (IFN-β) products and glatiramer acetate (GA) were the first available options and are now considered first-line agents for the treatment of MS. These medications have several years of f...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4110840/ https://ncbi.nlm.nih.gov/pubmed/25083243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098612462599 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|